ERBB2 and breast carcinoma: Notably, in heavily pretreated metastatic HR+/HER2-breast cancer, the combination of SY-5609 and Fulvestrant achieved disease stabilization in approximately 42% of evaluable patients, including those with prior Fulvestrant exposure and liver metastases (Juric et al., 2023).